Allison Barz Leahy, MD

Allison Barz Leahy, MD

Allison Barz Leahy, MD, is a fellow with the Cancer Immunotherpay Program at Children's Hospital of Philadelphia.

Locations: Main Campus
Appointments and Referrals: 1-800-TRY-CHOP (1-800-879-2467)

Education and Training

Medical School

MD - SUNY Upstate Medical University, Syracuse, NY

Internship

Medicine - Children’s Hospital of Philadelphia, Philadelphia, PA

Residency

Medicine - Children’s Hospital of Philadelphia, Philadelphia, PA

Fellowship

Pediatric Hematology/Oncology - Children’s Hospital of Philadelphia, Philadelphia, PA
Pediatric Hospital Epidemiology and Outcomes Research Training Program - Children’s Hospital of Philadelphia, Philadelphia, PA

Board Certification

Pediatrics

Graduate Degree

MA in Biological Sciences - Hunter College of the City of New York, New York, NY

Titles and Academic Titles

Fellow

Departments and Services

Publications

Papers

2017

Hill D, Leahy AB, Sciasci J, O’Neill S, Reilly A, Balamuth N, Seeholzer S, Spergel J, Brown-Whitehorn T. Medication contaminants as a potential cause of anaphylaxis to vincristine. Pediatr Blood Cancer. 2017 Aug 22. Epub ahead of print.

2016

Basch E, Deal A, Kris MG, Scher H, Hudis C, Sabbatini P, Rogak L, Bennett A, Dueck A, Atkinson T, Chou J, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan J, Schrag D. Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. J Clin Oncol. 2016 Feb 20; 34(6):557-65.

2014

Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014 Sep 29;106(9)

2013

Judson TJ, Bennett AV, Rogak LJ, Sit L, Barz A, et al. Feasibility of Long-Term Patient Self- Reporting of Toxicities From Home via the Internet During Routine Chemotherapy. J Clin Oncol. 2013 Jul 10;31(20):2580-5.

2009

Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris M, Schrag D. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. Journal of the National Cancer Institute. 2009 Dec 101(23): 1624-1632.

2007

Basch E, Iasonos A, Barz A, Culkin A, Kris M, Artz D, Fearn P, Speakman J, Scher H, McCabe M, Schrag D. Online symptom self-reporting by lung cancer patients using the Common Terminology Criteria for Adverse Events (CTCAE). Journal of Clinical Oncology. 2007 Dec 25(34): 5374-80.

Basch E, Artz D, Iasonos A, Speakman J, Shannon K, Lin K, Pun C, Yong H, Fearn P, Barz A, Scher H, McCabe M, Schrag D. Evaluation of an online platform for cancer patient selfreporting of chemotherapy toxicities. Journal of the American Medical Informatics Association. 2007 May 14(3): 264-268.

2006

Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. The Lancet Oncology. 2006 Nov 7(11): 883-4.

2004

Berwick M, Orlow I, Mahabir S, Myskowski P, Coit D, Brady M, Roy P, Song Y, Canchola R, Barz A, Bolognia J, Eng S, Elahi A, Begg CB. Estimating the relative risk of developingmelanoma in INK4A carriers. European Journal of Cancer Prevention. 2004 Feb 13(1): 65- 70.

2001

Orlow I, Roy P, Barz A, Canchola R, Song Y, Berwick M. Validation of denaturing high performance liquid chromatograph as a rapid detection method for the identification of human INK4A gene mutations. Journal of Molecular Diagnostics. 2001 Nov 3(4): 158-63.

Abstracts

2017

Getz K, Sung L, Ky B, Gerbing R, Leger K, Leahy AB, Sack L, Woods W, Alonzo T, Gamis A, Aplenc R. Incidence and Predictors of Anthracycline Cardiotoxicity among Children Treated on the AAML0531 Clinical Trial: A Report from the Children’s Oncology Group. Submitted to ASH Annual Meeting 2017.

Posters and Presentations

Invited Lectures

2017

Leahy AB. “Gabapentin as an antiemetic” – Children’s Oncology Group Cancer Control Webinar. September 2017.

Awards and Honors

2017-present, Recipient of NIH Loan Repayment Program in Pediatric Research
2017-2018, American Society of Hematology Clinical Research Training Program Fellow
2011, Dracker Family Scholarship
2011, Jack J. Schneider Scholarship
2011, Commendation, outstanding performance in clinical years, SUNY Upstate College of Medicine
2011, Gold Humanism Honor Society
2011, Alpha Omega Alpha

Editorial and Academic Positions

Editorial Positions

2017, Reviewer, Cancer
2017, Reviewer, Journal of Clinical Oncology

Academic and Institutional Committees

2016-present, Lead, Quality Improvement Project: Patient-reported outcomes in outpatient oncology. Division of Oncology,

2016-present, Fellow Liaison, Pediatric Hematology/Oncology Fellowship

Leadership and Memberships

Memberships in Professional Organizations

International

2017-present, International Society for Quality of Life Research

National

2017-present, American College of Epidemiology
2017-present, American Society of Hematology
2016-present, American Society of Pediatric Hematology and Oncology
2015-present, Children’s Oncology Group
2014-present, American Society of Clinical Oncology